Regencell Bioscience Holdings (RGC) Other Non-Current Assets (2020 - 2025)
Regencell Bioscience Holdings' (RGC) quarterly Other Non-Current Assets came in at $93439.0 in Q4 2025, up 0.53% on a QoQ basis from $92950.0 in Q2 2025.
Regencell Bioscience Holdings (RGC) Other Non-Current Assets (2020 - 2025) Analysis & Trends
Regencell Bioscience Holdings (RGC) has 6 years of Other Non-Current Assets data on file, last reported at $93439.0 in Q4 2025.
- Quarterly Other Non-Current Assets changed N/A year-over-year to $93439.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $93439.0 (changed N/A YoY) and the FY2025 annual result came in at $92950.0, down 4.85% from the prior year.
- Other Non-Current Assets improved to $93439.0 in Q4 2025, from $92950.0 in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $114302.0 in Q2 2022 to a low of $19106.0 in Q2 2021.
- A 5-year average of $87663.3 and a median of $95561.5 in 2024 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2022 — Other Non-Current Assets jumped 498.25% — and 2024, when it decreased 9.97%.
- Tracing RGC's Other Non-Current Assets over 5 years: stood at $19106.0 in 2021, then jumped by 498.25% to $114302.0 in 2022, then slipped by 5.08% to $108499.0 in 2023, then declined by 9.97% to $97684.0 in 2024, then decreased by 4.35% to $93439.0 in 2025.
- The last three Other Non-Current Assets figures came in at $93439.0 (Q4 2025), $92950.0 (Q2 2025), and $97684.0 (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | 56.35 Mn |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 1.79 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 384.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 503.80 Mn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 239.50 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 1.06 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 59.30 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 304.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 13.00 Mn |
| 10 | Regencell Bioscience Holdings | 2.61 Bn | 2.61 Bn | - | 93,439.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 93,439.00 |
| Jun 30, 2025 | 92,950.00 |
| Jun 30, 2024 | 97,684.00 |
| Jun 30, 2023 | 108,499.00 |
| Jun 30, 2022 | 114,302.00 |
| Jun 30, 2021 | 19,106.00 |
| Jun 30, 2020 | 18,718.00 |